| Suglat (ipragliflozin) / EMD Serono, Kotobuki, Astellas |
NCT01242215: A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Sulfonylurea in Type 2 Diabetic Patients |
|
|
| Completed | 3 | 243 | Japan | ipragliflozin, ASP1941, Placebo, Sulfonylurea, Glibenclamide, Gliclazide, Glimepiride | Astellas Pharma Inc | Type 2 Diabetes Mellitus | 04/12 | 04/12 | | |
|
NCT01242228: A Study to Assess the Safety and Efficacy of ASP1941 in Combination With Dipeptidyl Peptidase-4 (DPP-4) Inhibitor in Type 2 Diabetic Patients |
|
|
| Completed | 3 | 106 | Japan | ipragliflozin, ASP1941, DPP-4 inhibitor, saxagliptin, alogliptin, sitagliptin, vildagliptin | Astellas Pharma Inc | Type 2 Diabetes Mellitus | 06/12 | 06/12 | | |
NCT01316107: A Study to Assess Safety and Efficacy of ASP1941 in Combination With Nateglinide in Type 2 Diabetic Patients |
|
|
| Completed | 3 | 122 | Japan | ipragliflozin, ASP1941, nateglinide, Starsis, Fastic | Astellas Pharma Inc | Type 2 Diabetes Mellitus | 10/12 | 10/12 | | |
NCT01514838: A Study to Assess the Efficacy and Safety of ASP1941 in Asian Subjects With Type 2 Diabetes Mellitus |
|
|
| Terminated | 3 | 46 | RoW | ASP1941, ipragliflozin, acarbose, Placebo | Astellas Pharma Inc | Type II Diabetes Mellitus | 10/12 | 10/12 | | |
NCT01316094: A Study to Assess Efficacy and Safety of ASP1941 in Diabetic Patients With Renal Impairment |
|
|
| Completed | 3 | 165 | Japan | ASP1941, placebo | Astellas Pharma Inc | Type 2 Diabetes Mellitus | 11/12 | 11/12 | | |
NCT01505426: A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Metformin in Asian Diabetes Patients |
|
|
| Completed | 3 | 171 | RoW | ASP1941, ipragliflozin, metformin, Placebo | Astellas Pharma Inc | Type II Diabetes Mellitus | 01/13 | 01/13 | | |
NCT02452632: A Study to Assess the Efficacy and Safety of ASP1941 in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin |
|
|
| Completed | 3 | 143 | RoW | ASP1941, ipragliflozin, Suglat, Placebo | Astellas Pharma Korea, Inc. | Type 2 Diabetes Mellitus | 01/17 | 01/17 | | |
IMPRESSION, NCT02794792: A Study to Assess the Efficacy and Safety of Ipragliflozin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin |
|
|
| Completed | 3 | 268 | RoW | Ipragliflozin L-proline, Suglat, ASP1941, Metformin, Riomet, Glucophage, Glumetza, Glucophage XR, Fortamet, Placebo | Astellas Pharma Europe B.V. | Type 2 Diabetes Mellitus | 03/17 | 06/17 | | |
NCT02897219: A Study of ASP1941 in Combination With Insulin in Patients With Type 1 Diabetes Mellitus |
|
|
| Completed | 3 | 175 | Japan | ipragliflozin, ASP1941, Placebo, Insulin Therapy | Astellas Pharma Inc | Type 1 Diabetes Mellitus | 07/17 | 03/18 | | |
